Immune checkpoint inhibitors offer significant survival benefit, yet many patients do not respond to these treatments. Dosing optimization offers hope. Learn how to maximize therapeutic efficacy and minimize toxicity of ICIs in our guide.
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes.
Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position independent AI-focused biotechs as a threat to pharma’s internal R&D processes.
Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing for an IPO to bankroll phase 3 trials of its cell therapy in a lung condition and graft-versus-host disease.
This white paper delves into key challenges in ADC development and explores new drug product capabilities in cytotoxic drug development and manufacturing, accelerating timelines to IND filing and beyond.
The COVID-19 pandemic made us acutely aware of how vulnerable our noses are. The nose is a gateway to infection for respiratory pathogens like influenza and SARS-CoV-2, but our options to shield our nasal passageways from disease are limited.
Lundbeck has tapped Charles River Laboratories’ artificial intelligence capabilities to aid the discovery of neuroscience treatments, partnering with the service provider to use Logica in its research projects.
Eli Lilly is making another massive investment, revealing it will build a $4.5 billion R&D and manufacturing facility dubbed the Lilly Medicine Foundry that will “drive innovation in drug production and make medicines for clinical trials," the company said. It will add to the huge project the company is constructing in Lebanon, Indiana.
New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.
Dermatology biopharma Verrica Pharmaceuticals is lining up a cost-cutting plan that is prompting a major shake-up of its commercial teams and a narrowed focus on how it sells its only approved drug.
Two key senators are urging the Federal Trade Commission to investigate "co-manufacturing" arrangements that they fear pharmacy benefit managers may be using to stymie competition.
Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.
When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions.
Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market.
